Search

Your search keyword '"Sittig, Simone"' showing total 21 results
Start Over Author "Sittig, Simone"
21 results on '"Sittig, Simone"'

2. Supplementary Figures S1-S12 from Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines

Author

Bakdash, Ghaith, primary, Buschow, Sonja I., primary, Gorris, Mark A.J., primary, Halilovic, Altuna, primary, Hato, Stanleyson V., primary, Sköld, Annette E., primary, Schreibelt, Gerty, primary, Sittig, Simone P., primary, Torensma, Ruurd, primary, Duiveman-de Boer, Tjitske, primary, Schröder, Christoph, primary, Smits, Evelien L., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

3. Supplementary Dataset S1 from Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines

Author

Bakdash, Ghaith, primary, Buschow, Sonja I., primary, Gorris, Mark A.J., primary, Halilovic, Altuna, primary, Hato, Stanleyson V., primary, Sköld, Annette E., primary, Schreibelt, Gerty, primary, Sittig, Simone P., primary, Torensma, Ruurd, primary, Duiveman-de Boer, Tjitske, primary, Schröder, Christoph, primary, Smits, Evelien L., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

4. Supplementary Table and Figure Legends from Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines

Author

Bakdash, Ghaith, primary, Buschow, Sonja I., primary, Gorris, Mark A.J., primary, Halilovic, Altuna, primary, Hato, Stanleyson V., primary, Sköld, Annette E., primary, Schreibelt, Gerty, primary, Sittig, Simone P., primary, Torensma, Ruurd, primary, Duiveman-de Boer, Tjitske, primary, Schröder, Christoph, primary, Smits, Evelien L., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

5. Supplementary Table S2 from Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines

Author

Bakdash, Ghaith, primary, Buschow, Sonja I., primary, Gorris, Mark A.J., primary, Halilovic, Altuna, primary, Hato, Stanleyson V., primary, Sköld, Annette E., primary, Schreibelt, Gerty, primary, Sittig, Simone P., primary, Torensma, Ruurd, primary, Duiveman-de Boer, Tjitske, primary, Schröder, Christoph, primary, Smits, Evelien L., primary, Figdor, Carl G., primary, and de Vries, I. Jolanda M., primary

Published
2023
Full Text
View/download PDF

8. Human type 1 and type 2 conventional dendritic cells express indoleamine 2,3‐dioxygenase 1 with functional effects on T cell priming

Author

Sittig, Simone P., primary, van Beek, Jasper J. P., additional, Flórez‐Grau, Georgina, additional, Weiden, Jorieke, additional, Buschow, Sonja I., additional, van der Net, Mirjam C., additional, van Slooten, Rianne, additional, Verbeek, Marcel M., additional, Geurtz, P. Ben H., additional, Textor, Johannes, additional, Figdor, Carl G., additional, de Vries, I. Jolanda M., additional, and Schreibelt, Gerty, additional

Published
2021
Full Text
View/download PDF

9. Expansion of a <tex>BDCA^{+}CD14^{+}$</tex> myeloid cell population in melanoma patients may attenuate the efficacy of dendritic cell vaccines

Author

Bakdash, Ghaith, Buschow, Sonja I., Gorris, Mark A. J., Halilovic, Altuna, Hato, Stanleyson V., Skold, Annette E., Schreibelt, Gerty, Sittig, Simone P., Torensma, Ruurd, Duiveman-de Boer, Tjitske, Schroeder, Christoph, Smits, Evelien, Figdor, Carl G., and de Vries, I. Jolanda M.

Subjects
Human medicine
Abstract

The tumor microenvironment is characterized by regulatory T cells, type II macrophages, myeloid-derived suppressor cells, and other immunosuppressive cells that promote malignant progression. Here we report the identification of a novel BDCA1(+)CD14(+) population of immunosuppressive myeloid cells that are expanded in melanoma patients and are present in dendritic cell-based vaccines, where they suppress CD4(+) T cells in an antigen-specific manner. Mechanistic investigations showed that BDCA1(+)CD14(+) cells expressed high levels of the immune checkpoint molecule PD-L1 to hinder T-cell proliferation. While this BDCA1(+)CD14(+) cell population expressed markers of both BDCA1(+) dendritic cells and monocytes, analyses of function, transcriptome, and proteome established their unique nature as exploited by tumors for immune escape. We propose that targeting these cells may improve the efficacy of cancer immunotherapy. (C) 2016 AACR.

Published
2016

10. GBF1- and ACBD3-Independent Recruitment of PI4KIIIβ to Replication Sites by Rhinovirus 3A Proteins

Author

Dorobantu, Cristina M, Ford-Siltz, Lauren A, Sittig, Simone P, Lanke, Kjerstin H W, Belov, George A, van Kuppeveld, Frank J M, van der Schaar, Hilde M, LS Virologie, Strategic Infection Biology, and I&I SIB1

Subjects
stomatognathic system, viruses, Coronacrisis-Taverne, virus diseases, Genome Replication and Regulation of Viral Gene Expression
Abstract

PI4KIIIβ recruitment to Golgi membranes relies on GBF1/Arf and ACBD3. Enteroviruses such as poliovirus and coxsackievirus recruit PI4KIIIβ to their replication sites via their 3A proteins. Here, we show that human rhinovirus (HRV) 3A also recruited PI4KIIIβ to replication sites. Unlike other enterovirus 3A proteins, HRV 3A failed to bind GBF1. Although HRV 3A was previously shown to interact with ACBD3, our data suggest that PI4KIIIβ recruitment occurred independently of both GBF1 and ACBD3.

Published
2014

11. Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines

Author

Bakdash, Ghaith, primary, Buschow, Sonja I., additional, Gorris, Mark A.J., additional, Halilovic, Altuna, additional, Hato, Stanleyson V., additional, Sköld, Annette E., additional, Schreibelt, Gerty, additional, Sittig, Simone P., additional, Torensma, Ruurd, additional, Duiveman-de Boer, Tjitske, additional, Schröder, Christoph, additional, Smits, Evelien L., additional, Figdor, Carl G., additional, and de Vries, I. Jolanda M., additional

Published
2016
Full Text
View/download PDF

12. Lipid peroxidation causes endosomal antigen release for cross-presentation

Author

Dingjan, Ilse, primary, Verboogen, Daniëlle RJ, additional, Paardekooper, Laurent M, additional, Revelo, Natalia H, additional, Sittig, Simone P, additional, Visser, Linda J, additional, Mollard, Gabriele Fischer von, additional, Henriet, Stefanie SV, additional, Figdor, Carl G, additional, ter Beest, Martin, additional, and van den Bogaart, Geert, additional

Published
2016
Full Text
View/download PDF

16. Clonal expansion of renal cell carcinoma-infiltrating T lymphocytes

Author

Sittig, Simone, Køllgaard, Tania, Grønbæk, Kirsten, Idorn, Manja, Hennenlotter, Jörg, Stenzl, Arnulf, Gouttefangeas, Cécile, Thor Straten, Per, Sittig, Simone, Køllgaard, Tania, Grønbæk, Kirsten, Idorn, Manja, Hennenlotter, Jörg, Stenzl, Arnulf, Gouttefangeas, Cécile, and Thor Straten, Per

Published
2013

20. Targeting Uptake Receptors on Human Plasmacytoid Dendritic Cells Triggers Antigen Cross-Presentation and Robust Type I IFN Secretion.

Author

Jurjen Tel, Sittig, Simone P., Blom, Rebecca A. M., Cruz, Luis J., Schreibelt, Gerty, Figdor, Carl G., and de Vries, I. Jolanda M.

Subjects
*DENDRITIC cells, *INTERFERONS, *LECTINS, *CANCER cells, *TUMOR necrosis factors
Abstract

Plasmacytoid dendritic cells (pDCs) play a crucial role in initiating immune responses by secreting large amounts of type I IFNs. Currently, the role for human pDCs as professional APCs in the cross-presentation of exogenous Ags is being re-evaluated. Human pDCs are equipped with a broad repertoire of Ag uptake receptors and an efficient Ag-processing machinery. In this study, we set out to investigate which receptor can best be deployed to deliver Ag to pDCs for Ag (cross-)presentation. We show that targeting nanoparticles to pDCs via the C-type lectins DEC-205, DC immunoreceptor, blood DC Ag-2, or the FcR CD32 led to uptake, processing, and (cross-) presentation of encapsulated Ag to both CD4+ and CD8+ T cells. This makes these receptors good candidates for potential in vivo targeting of pDCs by nanocarriers. Notably, the coencapsulated TLR7 agonist R848 efficiently activated pDCs, resulting in phenotypical maturation as well as robust IFN-a and TNF-a production. Taken together, their cross-presentation capacity and type I IFN production to further activate components of both the innate and adaptive immune system mark pDCs as inducers of potent antitumor responses. These findings pave the way to actively recruit human pDCs for cellular cancer immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

21. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+T cells despite lower Ag uptake than myeloid dendritic cell subsets

Author

Tel, Jurjen, Schreibelt, Gerty, Sittig, Simone P., Mathan, Till S.M., Buschow, Sonja I., Cruz, Luis J., Lambeck, Annechien J.A., Figdor, Carl G., and de Vries, I. Jolanda M.

Abstract

In human peripheral blood, 4 populations of dendritic cells (DCs) can be distinguished, plasmacytoid dendritic cells (pDCs) and CD16+, CD1c+, and BDCA-3+myeloid DCs (mDCs), each with distinct functional characteristics. DCs have the unique capacity to cross-present exogenously encountered antigens (Ags) to CD8+T cells. Here we studied the ability of all 4 blood DC subsets to take up, process, and present tumor Ags to T cells. Although pDCs take up less Ags than CD1c+and BDCA3+mDCs, pDCs induce potent Ag-specific CD4+and CD8+T-cell responses. We show that pDCs can preserve Ags for prolonged periods of time and on stimulation show strong induction of both MHC class I and II, which explains their efficient activation of both CD4+and CD8+T cells. Furthermore, pDCs cross-present soluble and cell-associated tumor Ags to cytotoxic T lymphocytes equally well as BDCA3+mDCs. These findings, and the fact that pDCs outnumber BDCA3+mDCs, both in peripheral blood and lymph nodes, together with their potent IFN-I production, known to activate both components of the innate and adaptive immune system, put human pDCs forward as potent activators of CD8+T cells in antitumor responses. Our findings may therefore have important consequences for the development of antitumor immunotherapy.

Published
2013
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results